AGLE
Aeglea BioTherapeutics, Inc.
Set alert
52-week range unavailable
- Open
- 10.87
- Prev close
- 12.01
- Mkt cap
- 48.63M
- Vol
- 43.24K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.69
- High
- 12.34
- Forward P/E
- -6.53
- Beta
- 2.57
- Short ratio
- 3.68
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2023
- 50-d avg
- 12.64
- 200-d avg
- 9.84
- 1y target
- 17.50
Key statistics
- Market cap
- 48.63M
- Enterprise value
- 232.13M
- Trailing P/E
- 0.00
- Forward P/E
- -6.53
- PEG ratio
- 0.00
- Price / sales
- 46.14
- Price / book
- 0.00
- EPS (TTM)
- -74.15
- Beta
- 2.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.05M
- Revenue growth
- 0.00%
- Free cash flow
- -2.62M
- Total cash
- 203.60M
- Total debt
- 0
- Return on equity
- -281.41%
- Shares outstanding
- 4.05M
- Short % of float
- 3.47%
- 50-day average
- 12.64
- 200-day average
- 9.84
Analyst view
Consensus: buy
- Target (low)
- 12.00
- Target (mean)
- 17.50
- Target (high)
- 23.00
- Strong buy1
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 9, 2023
Expected Nov 9, 2023. Consensus EPS estimate -0.91.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2023 | Sep 1, 2023 | -0.44 | — | — | — |
| Aug 11, 2023 | Jun 1, 2023 | -4.50 | — | — | — |
| May 11, 2023 | Mar 1, 2023 | -4.75 | — | — | — |
| Mar 2, 2023 | Dec 1, 2022 | -5.00 | — | — | — |
| Nov 3, 2022 | Sep 1, 2022 | -6.00 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | -6.50 | — | — | — |
About Aeglea BioTherapeutics, Inc.
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aeglea.com
News
- Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD
- Aeglea BioTherapeutics Announces Grants of Inducement Awards
- Aeglea BioTherapeutics Announces Grants of Inducement Awards
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Aeglea BioTherapeutics (NASDAQ: AGLE)
- Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences
- Aeglea BioTherapeutics Announces Grants of Inducement Awards
- Aeglea BioTherapeutics to Participate in Upcoming September Conference
- Aeglea BioTherapeutics Announces Reverse Stock Split
- Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results
- Polar Capital Holdings Plc Enters Stake in Aeglea BioTherapeutics Inc
Your note
Sign in to keep a note on AGLE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALSPAUGH JONATHAN D. | Chief Financial Officer | Purchase | Mar 10, 2022 | 165,372 |
| HANLEY MICHAEL CONICK JR. | Officer | Purchase | Jun 7, 2022 | 36,200 |
| QUINN ANTHONY G | Chief Executive Officer | Purchase | Mar 15, 2022 | 816,835 |
| SHANAFELT ARMEN B | Director | Purchase | Dec 12, 2021 | 150,000 |
| SOUZA MARCIO SILVA DE | Director | Purchase | Aug 24, 2022 | 90,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fairmount Funds Management LLC | 0.37% | 378,422 | 4.26M | Jun 29, 2023 |
| Wellington Management Group, LLP | 0.35% | 352,767 | 3.97M | Jun 29, 2023 |
| VR Adviser, LLC | 0.25% | 253,729 | 2.86M | Jun 29, 2023 |
| EcoR1 Capital, LLC | 0.20% | 200,000 | 2.25M | Jun 29, 2023 |
| Affinity Asset Advisors, Llc | 0.19% | 196,000 | 2.21M | Jun 29, 2023 |
| Driehaus Capital Management, LLC | 0.18% | 185,734 | 2.09M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Core S&P Total U.S. Stock Market ETF | 0.03% | 35,083 | 504.32K | Aug 30, 2023 |
| Vanguard Extended Market Index Fund | 0.02% | 25,294 | 284.87K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.01% | 12,760 | 41.44K | May 30, 2023 |